Abstract
Post Hoc Analyses of Biomarkers Predictive of a Renal Response to Intravenous (IV) Belimumab (BEL) Plus Standard Therapy (ST) in Patients with Lupus Nephritis (LN)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have